STOCK TITAN

Vanguard (TRVI) amends 13G/A after Jan 12, 2026 realignment

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Trevi Therapeutics Inc: An amended Schedule 13G/A filed by The Vanguard Group reports zero shares beneficially owned and 0% of the class as of the filing. The filing explains an internal realignment at The Vanguard Group, Inc. on January 12, 2026 that led certain subsidiaries to report separately.

The filing is administrative: it lists Vanguard's address and states Vanguard and related investment vehicles have the right to receive dividends or proceeds where applicable, and certifies that no single other person holds more than 5% of the class. The form is signed on 03/27/2026.

Positive

  • None.

Negative

  • None.

Insights

Administrative update showing no beneficial ownership reported by Vanguard for Trevi.

The amendment documents an internal reorganization at The Vanguard Group, Inc. on January 12, 2026, and states certain subsidiaries now report ownership separately. The schedule reports 0 shares and 0% beneficial ownership.

This is a disclosure and reporting change rather than an economic transaction. Cash‑flow treatment and any subsidiary holdings are not quantified in this excerpt; subsequent filings by specific Vanguard subsidiaries may show holdings if present.






89532M101

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

Does The Vanguard Group report any ownership in TRVI in this amendment?

No. The filing states 0 shares beneficially owned and 0% of the class. It records an administrative disaggregation after an internal Vanguard realignment on January 12, 2026.

Why does Vanguard say ownership is reported separately after January 12, 2026?

Because of an internal realignment at The Vanguard Group, Inc., certain subsidiaries now report ownership on a disaggregated basis in reliance on SEC Release No. 34-39538 (January 12, 1998). The filing cites that release verbatim.

Who signed the Schedule 13G/A for Vanguard on TRVI and when?

The form is signed by Ashley Grim, Head of Global Fund Administration, with an execution date of 03/27/2026, certifying the amendment's disclosures on behalf of The Vanguard Group.

Does this amendment indicate any Vanguard subsidiary holds more than 5% of Trevi?

No. The filing explicitly states that no one other person's interest in the securities reported herein is more than 5%. It also notes pooled accounts and registered investment companies are not required to be listed.

Will this Schedule 13G/A cause immediate market transactions or company action?

No. This document is a reporting amendment reflecting organizational reporting changes; it does not itself record purchases, sales, or issuer actions. It updates how Vanguard reports beneficial ownership after its internal realignment.
Trevi Therapeutics

NASDAQ:TRVI

View TRVI Stock Overview

TRVI Rankings

TRVI Latest News

TRVI Latest SEC Filings

TRVI Stock Data

1.52B
113.97M
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN